- Organigram to supply the medical division of German cannabis company Sanity Group with high-quality medical flower for distribution in Germany.
- Germany is expected to legalize recreational cannabis and remains the largest addressable cannabis market in Europe as a result.
- Both Organigram and Sanity Group have received strategic investments from BAT
May 23, 2023 06:00 AM Eastern Daylight Time
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce today that it has entered into a supply agreement (“the Agreement”) for dried flower with the medical division of German cannabis company Sanity Group, a health and life sciences company based in Berlin, Germany, dedicated to the medical applications of cannabinoids. Through exports from its flagship state-of-the-art cultivation facility in Moncton, Organigram already services medical patients in Israel and Australia, and will now add Germany to its growing list of international markets.
Under the terms of the Agreement, the Company will provide high-quality, indoor-grown dried flower product to Sanity Group and grant Sanity Group strain exclusivity on certain genetics.
“With the German cannabis industry slowly moving toward a recreational adult-use model, we are excited to begin solidifying our relationships with reputable medical cannabis product developers and distributors like Sanity Group,” says Beena Goldenberg, Chief Executive Officer of Organigram. “We are committed to providing customers and medical patients in Australia, Israel, and now Germany, with high-quality cannabis, produced through industry-leading research, development and consumer-led insights.”
“We look forward to bringing Organigram’s high-quality indoor-grown flower to our German medical patients,” said Finn Age Hänsel, Managing Director & Founder of Sanity Group. “Organigram consistently ranks as a leader in flower sales nationally in Canada and will be providing us with exclusivity on certain strains within the German market.”
Activities under the Agreement are subject to compliance with all applicable laws, including receipt of all requisite approvals from Health Canada, the German Ministry of Health, and any other applicable regulatory authorities.
